Astrid Pavlovsky
YOU?
Author Swipe
View article: CNS Prophylaxis in patients with DLBC: Lymphoma Subcommittee of the Argentinian Society of Hematology experience
CNS Prophylaxis in patients with DLBC: Lymphoma Subcommittee of the Argentinian Society of Hematology experience Open
View article: Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial Open
PURPOSE Prognosis for patients with refractory/relapsed large B-cell lymphoma (LBCL) considered ineligible for curative-intent therapy is poor. The combination of mosunetuzumab, a T-cell–engaging bispecific antibody, and polatuzumab vedoti…
View article: LBA3 | MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN IS SUPERIOR TO R‐GemOx IN TRANSPLANT‐INELIGIBLE PATIENTS WITH R/R LBCL: PRIMARY RESULTS OF THE PHASE III SUNMO TRIAL
LBA3 | MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN IS SUPERIOR TO R‐GemOx IN TRANSPLANT‐INELIGIBLE PATIENTS WITH R/R LBCL: PRIMARY RESULTS OF THE PHASE III SUNMO TRIAL Open
View article: 891 | INVESTIGATING GLOBAL GENDER DEMOGRAPHICS AND EQUITY AMONG HEMATOLOGISTS
891 | INVESTIGATING GLOBAL GENDER DEMOGRAPHICS AND EQUITY AMONG HEMATOLOGISTS Open
View article: 14 | PERFORMANCE OF BASELINE AND END‐OF‐TREATMENT FDG‐PET RADIOMICS IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA: DATA FROM INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0
14 | PERFORMANCE OF BASELINE AND END‐OF‐TREATMENT FDG‐PET RADIOMICS IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA: DATA FROM INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0 Open
View article: 363 | REAL‐WORLD EVIDENCE OF BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS TRANSPLANT IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: 2‐YEAR FOLLOW‐UP FROM THE GATLA STUDY
363 | REAL‐WORLD EVIDENCE OF BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS TRANSPLANT IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: 2‐YEAR FOLLOW‐UP FROM THE GATLA STUDY Open
View article: 402 | RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMAS: REPORT ON 641 PATIENTS FROM THE T‐CELL PROJECT 2.0
402 | RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMAS: REPORT ON 641 PATIENTS FROM THE T‐CELL PROJECT 2.0 Open
View article: Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis
Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis Open
View article: Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)
Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35) Open
Primary lymphoma of the female genital tract (PLFGT) is a rare type of extranodal lymphoma. In this retrospective study from the International Extranodal Lymphoma Study Group, we analyzed clinical data from 60 women diagnosed with PLFGT be…
View article: Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method
Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method Open
The authors agreed that BV-AVD could be considered a new treatment option in high-risk patients. However health system-dependent factors (such as high cost, lack of availability, reimbursement difficulties, irregular delivery, and issues w…
View article: Epidemiology, Clinical Features, and Outcomes of Peripheral T-Cell Lymphoma in Latin America
Epidemiology, Clinical Features, and Outcomes of Peripheral T-Cell Lymphoma in Latin America Open
View article: Personalised therapy in follicular lymphoma – is the dial turning?
Personalised therapy in follicular lymphoma – is the dial turning? Open
Follicular lymphoma is the most common indolent lymphoma accounting for approximately 20%–25% of all new non‐Hodgkin lymphoma diagnoses in western countries. Whilst outcomes are mostly favorable, the spectrum of clinical phenotypes include…
View article: Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T‐cell Project 2.0.
Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T‐cell Project 2.0. Open
Introduction: Mature T and NK-cell lymphomas represent a heterogeneous group of rare lymphoid disorders arising from mature T cells of post-thymic origin. The T-cell Project 2.0 (TCP2) was launched in 2018 with the aim of better understand…
View article: Long term outcome of Peripheral T Cell Lymphomas: 10y follow‐up analysis of the International Prospective T Cell Project Network
Long term outcome of Peripheral T Cell Lymphomas: 10y follow‐up analysis of the International Prospective T Cell Project Network Open
Introduction: Peripheral T cell lymphomas (PTCLs) are a rare, heterogeneous group of hematological malignancies with too often poor prognosis for almost all subtypes. The T-Cell Project (TCP; registered at clinicaltrials.gov identifier: 01…
View article: SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA
SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA Open
Introduction: Aggressive non-Hodgkin lymphomas (aNHL) are a diverse group of neoplasms, of which diffuse large B-cell lymphoma (DLBCL) is the most common subtype (Thandra, 2021). Patients (pts) with relapsed/refractory (R/R) DLBCL after on…
View article: Primary lymphoma of the female genital tract: a retrospective survey of the International Extranodal Lymphoma Study Group (IELSG35)
Primary lymphoma of the female genital tract: a retrospective survey of the International Extranodal Lymphoma Study Group (IELSG35) Open
Introduction: Primary lymphoma of the female genital tract (PLFGT) is an uncommon extranodal lymphoma. There are few reported series of PLFGT in the literature, and most of them are case reports. Methods: We retrospectively collected and a…
View article: PROSPECTIVE REAL WORLD EVIDENCE: USE OF BRENTUXIMAB VEDOTIN AS CONSOLIDATION THERAPY AFTER AUTOLOGOUS TRANSPLANT IN HODGKIN LYMPHOMA. AN INTERIM ANALYSIS, ON BEHALF OF GATLA
PROSPECTIVE REAL WORLD EVIDENCE: USE OF BRENTUXIMAB VEDOTIN AS CONSOLIDATION THERAPY AFTER AUTOLOGOUS TRANSPLANT IN HODGKIN LYMPHOMA. AN INTERIM ANALYSIS, ON BEHALF OF GATLA Open
Introduction: Consolidation therapy with brentuximab vedotin (BV) after autologous stem cell transplant (auto-HCT) in the AETHERA trial, reported improved progression free survival (PFS) in patients with classical Hodgkin lymphoma (cHL) wi…
View article: CNS PROPHYLAXIS IN PATIENTS WITH DLBCL: A REAL WORLD EXPERIENCE ON BEHALF OF THE LYMPHOMA SUBCOMMITTEE OF THE ARGENTINE SOCIETY OF HEMATOLOGY
CNS PROPHYLAXIS IN PATIENTS WITH DLBCL: A REAL WORLD EXPERIENCE ON BEHALF OF THE LYMPHOMA SUBCOMMITTEE OF THE ARGENTINE SOCIETY OF HEMATOLOGY Open
Introduction: Although central nervous system (CNS) relapse in patients with Diffuse Large B-Cell Lymphoma (DLBCL) is an infrequent event, the mortality rate is high. The efficacy of strategies currently used to prevent it, has been challe…
View article: Toxicity and Outcomes of Ibrutinib in Chronic Lymphatic Leukemia-Real-World Results from the Study of 215 Patients in Argentina
Toxicity and Outcomes of Ibrutinib in Chronic Lymphatic Leukemia-Real-World Results from the Study of 215 Patients in Argentina Open
Different pivotal works allowed the approval of ibrutinib as a CLL treatment, both in the first line and in relapsed/refractory patients, the adverse effects differ from conventional chemotherapy, the discontinuation rate was 10%, but in d…
View article: Proyecto célula T 2.0: análisis interino a junio 2021
Proyecto célula T 2.0: análisis interino a junio 2021 Open
Las neoplasias linfoides T/NK maduras (LNH-T) son infrecuentes y conforman un grupo heterogéneo de enfermedades. En Argentina y en el resto de América Latina no existen datos epidemiológicos sobre la presentación, metodología diagnóstica, …
View article: The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee Open
Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broa…
View article: S222: MATURE T AND NK CELL LYMPHOMAS CLASSIFIED ACCORDING TO 2016 WHO CLASSIFICATION. A REPORT OF THE INTERNATIONAL PROSPECTIVE T-CELL PROJECT 2.0.
S222: MATURE T AND NK CELL LYMPHOMAS CLASSIFIED ACCORDING TO 2016 WHO CLASSIFICATION. A REPORT OF THE INTERNATIONAL PROSPECTIVE T-CELL PROJECT 2.0. Open
Background: Mature T and NK-cell lymphomas represent a heterogeneous group of rare lymphoid disorders arising from mature T cells of post-thymic origin. In 2018 the International T-cell non-Hodgkin’s Lymphoma Study Group launched the T-cel…
View article: PET/CT Imaging of Lymphoma Outside the Western World
PET/CT Imaging of Lymphoma Outside the Western World Open
FIGURE 4. Vultocinus anfractus, new genus, new species. Holotype male (cl 19.5 mm, cw 20.3 mm) (NMCR 19114), Philippines. A, outer surface of right chela; B, outer surface of left chela; C, right side of thoracic sternum showing ventral su…
View article: Desbalances genómicos del locus 9p24.1 en pacientes argentinos con linfoma de Hodgkin clásico
Desbalances genómicos del locus 9p24.1 en pacientes argentinos con linfoma de Hodgkin clásico Open
Introducción: El linfoma de Hodgkin clásico presenta escasas células de Reed Sternberg/Hodgkin inmersas en un abundante microambiente tumoral. Los desbalances genómicos del locus 9p24.1 han sido asociados con alteraciones en la expresión d…
View article: SUBTYPES OF MATURE T AND NK CELL LYMPHOMAS ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0
SUBTYPES OF MATURE T AND NK CELL LYMPHOMAS ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0 Open
Introduction: Mature T and NK-cell lymphomas represent a heterogeneous group of lymphoid disorders (29 subtypes according to the 2016 WHO classification) arising from mature T cells of post-thymic origin with different morphological charac…
View article: Better understanding and new challenges in high grade lymphomas
Better understanding and new challenges in high grade lymphomas Open
Diffuse large B-cell lymphoma (DLBCL), comprise the most commonly diagnosed non-Hodgkin lymphoma. Approximately 60–65% of patients can be cured with standard front-line therapy R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine …
View article: Impact of Ibrutinib in Quality of Life (QoL) in Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of Real-World Experience
Impact of Ibrutinib in Quality of Life (QoL) in Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of Real-World Experience Open
View article: IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA‐NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T‐CELL PROJECT
IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA‐NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T‐CELL PROJECT Open
Introduction: Extra-nodal NK/T cell lymphoma (NKTCL) is a distinct clinicopathological entity characterised by a cytotoxic T or NK cell phenotype and invariable Epstein Barr virus (EBV) infection of the malignant clone. An invasive nasal a…
View article: SOXC and MiR17‐92 gene expression profiling defines two subgroups with different clinical outcome in mantle cell lymphoma
SOXC and MiR17‐92 gene expression profiling defines two subgroups with different clinical outcome in mantle cell lymphoma Open
Mantle cell lymphoma (MCL) is a heterogeneous B‐cell lymphoid malignancy where most patients follow an aggressive clinical course whereas others are associated with an indolent performance. SOX4 , SOX11 , and SOX12 belong to SOXC family of…